Israel Active

Israel’s Elgan Pharma (see previously) has been awarded a 2.36 million euros grant by the European Innovation Council. It will support a Phase III study of its ELGN-GL oral insulin-based formulation that helps the development of a preemie’s gastrointestinal (GI) system.

Israel’s Nasus Pharma (see previously) has reported positive results from its latest clinical study of its FMXIN002 intranasal Epinephrine powder spray device. It provides a safe and effective rescue for the emergency treatment of life-threatening allergic reactions.

Israel’s UroGen Pharma (see previously) has published positive results from two clinical trials of bladder cancer treatment UGN-102. The therapy can benefit some 80,000 patients. Trial success (65%) was similar to patients who had surgery but with a 55% less re-occurrence rate.

A woman with Stevens-Johnson Syndrome (SJS) was saved by doctors at Soroka-University Medical Center in Beersheba. The genetic disease progresses into toxic epidermal necrolysis – a life threatening condition causing 30% of the skin to peel off.

Israel’s Pharma Two B (see previously) is presenting the full results of its Phase 3 trial of its once-a-day injection of its P2B001 treatment for Parkinson’s disease. P2B001 combines low-dose pramipexole with low-dose rasagiline. It relieves PD symptoms with few side effects.

Sheba Medical Center has deployed a new accelerated, AI-powered cancer diagnostics research platform to improve patient diagnosis, treatment, and outcomes. It utilizes solutions of various Israeli startups, including that of Imagene (see previously).

Healthcare app Together by Renee is integrating the video-based biomarker check technology from Israel’s Binah.ai (see previously). The platform allows US seniors to easily check and share vital signs with caregivers and family, using their smartphone cameras.

Joint Israeli & US research has revealed crucial insights into the early development of specialized tissues that protect the fetus during human pregnancy. The findings can potentially help prevent dangerous pregnancy complications, like pre-eclampsia and preterm birth.

Israel’s Sofwave Medical (see previously) has received US FDA approval for its treatment for acne scars. 88% of patients reported an improvement in a clinical study of Sofwave’s Synchronous Ultrasound Parallel Beam (SUPERB) technology.

Israel’s Neurosteer (see previously) has developed a musical test for the early detection of Parkinson’s Disease as well as Alzheimer’s and other forms of dementia.  Patients conduct a series of musical tasks while sensors connected to an EEG device record their brain activity.